Edition:
United Kingdom

JCR Pharmaceuticals Co Ltd (4552.T)

4552.T on Tokyo Stock Exchange

4,590JPY
20 Nov 2017
Change (% chg)

¥35 (+0.77%)
Prev Close
¥4,555
Open
¥4,600
Day's High
¥4,740
Day's Low
¥4,535
Volume
217,300
Avg. Vol
149,439
52-wk High
¥4,740
52-wk Low
¥2,133

Chart for

About

JCR Pharmaceuticals Co., Ltd. is a Japan-based company primarily engaged in the pharmaceutical business, as well as the medical and research equipment business. The Pharmaceutical business engages in the research, production, purchase and sale of medical drugs and pharmaceutical raw materials. The Medical and Research Equipment... (more)

Overall

Beta: 1.18
Market Cap(Mil.): ¥119,311.40
Shares Outstanding(Mil.): 32.42
Dividend: 11.00
Yield (%): 0.60

Financials

  Industry Sector
P/E (TTM): -- 31.15 16.44
EPS (TTM): -- -- --
ROI: -- 14.99 10.62
ROE: -- 16.33 14.20

BRIEF-JCR Pharmaceuticals to initiate development of JR-171, new drug candidate for Hurler Syndrome using J-Brain Cargo

* Says it will initiate development of JR-171, new drug candidate for Hurler Syndrome using J-Brain Cargo

26 Oct 2017

BRIEF-NanoCarrier and JCR conclude collaborative research agreement for drug delivery to the brain for nucleic acid medicines

* Says it and NanoCarrier Co., Ltd conclude collaborative research agreement for drug delivery to the brain for nucleic acid medicines

10 Oct 2017

BRIEF-JCR Pharmaceuticals submits application for marketing approval of JR-051 for Fabry disease

* Says it has submitted an application for marketing approval on JR-051 (recombinant alpha-galactosidase A), an enzyme replacement therapy (ERT) for Fabry disease to Ministry of Health, Labour and Welfare

29 Sep 2017

BRIEF-JCR Pharmaceuticals completes share repurchase through ToSTNeT-3

* Says it completed repurchase of 854,100 shares of its common stock, for 2.62 billion yen in total, through ToSTNeT-3, on Sept. 22

22 Sep 2017

BRIEF- JCR Pharmaceuticals to repurchase shares

* Says it will repurchase up to 940,000 shares of its common stock, representing 2.7 percent of outstanding, on Sept. 22

21 Sep 2017

BRIEF- JCR Pharmaceuticals announces shareholding structure change

* Says its top shareholder GLAXO GROUP LIMITED will cut voting power in the company to 0 percent from 25.2 percent

21 Sep 2017

BRIEF- JCR Pharmaceuticals announces business and capital alliance with Medipal Holdings

* Says it signed a business and capital alliance with Medipal Holdings Corp

21 Sep 2017

BRIEF- JCR Pharmaceuticals to develop allogeneic regenerative medical product using DPCs with Teijin

* Says it entered into co-development and license agreement with Teijin Ltd, regarding JTR-161, an allogeneic regenerative medical product using dental pulp stem cells (DPCs) for the indication of acute cerebral infarction (stroke) for Japan, on July 18

18 Jul 2017

Earnings vs. Estimates